Halozyme Therapeutics (NASDAQ:HALO) Updates FY22 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALOGet Rating) issued an update on its FY22 earnings guidance on Wednesday morning. The company provided EPS guidance of $2.05-2.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.19. The company issued revenue guidance of $530-560 million, compared to the consensus revenue estimate of $553.50 million.Halozyme Therapeutics also updated its FY 2022 guidance to $2.050-$2.200 EPS.

A number of brokerages recently commented on HALO. Piper Sandler lowered their price objective on Halozyme Therapeutics from $43.00 to $42.00 in a research report on Wednesday, February 23rd. StockNews.com raised shares of Halozyme Therapeutics from a hold rating to a buy rating in a research note on Monday. Finally, Zacks Investment Research raised shares of Halozyme Therapeutics from a strong sell rating to a hold rating and set a $37.00 price objective on the stock in a research note on Monday, March 14th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Buy and an average target price of $47.83.

NASDAQ HALO traded down $0.61 during trading on Wednesday, reaching $41.01. 14,337 shares of the stock traded hands, compared to its average volume of 895,423. Halozyme Therapeutics has a fifty-two week low of $31.36 and a fifty-two week high of $51.57. The company has a quick ratio of 7.45, a current ratio of 7.91 and a debt-to-equity ratio of 4.00. The firm has a market cap of $5.65 billion, a price-to-earnings ratio of 15.13 and a beta of 1.32. The stock’s 50-day moving average price is $36.66 and its 200 day moving average price is $36.85.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last announced its quarterly earnings results on Tuesday, February 22nd. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $102.00 million during the quarter, compared to analyst estimates of $97.10 million. Halozyme Therapeutics had a net margin of 90.84% and a return on equity of 164.68%. Analysts anticipate that Halozyme Therapeutics will post 1.99 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Halozyme Therapeutics by 0.7% during the 4th quarter. BlackRock Inc. now owns 19,439,863 shares of the biopharmaceutical company’s stock worth $781,676,000 after purchasing an additional 144,483 shares in the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Halozyme Therapeutics by 4.5% during the fourth quarter. Allianz Asset Management GmbH now owns 586,274 shares of the biopharmaceutical company’s stock worth $23,575,000 after buying an additional 25,161 shares in the last quarter. Deutsche Bank AG raised its position in Halozyme Therapeutics by 6.3% in the 4th quarter. Deutsche Bank AG now owns 111,307 shares of the biopharmaceutical company’s stock valued at $4,476,000 after buying an additional 6,617 shares during the last quarter. California State Teachers Retirement System lifted its stake in Halozyme Therapeutics by 1.6% in the 4th quarter. California State Teachers Retirement System now owns 195,973 shares of the biopharmaceutical company’s stock valued at $7,880,000 after acquiring an additional 3,170 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Halozyme Therapeutics by 5.1% in the 4th quarter. Parametric Portfolio Associates LLC now owns 293,558 shares of the biopharmaceutical company’s stock valued at $11,804,000 after acquiring an additional 14,233 shares in the last quarter. 90.21% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics (Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.